PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21628860-2	2011	It is considered that BCL2 translocation precedes MYC events in lymphomagenesis of DHL.	Cysteamine	83-86	BCL2 apoptosis regulator	Homo sapiens	22-26	
24234731-4	2014	DHL is group accompanied by IGH-BCL2 and MYC rearrangement, behaving highly aggressively, with a complex and distinct karyotype which can not be extrapolated solely by morphological pathological assessment, since it has not been entirely characteristic.	Cysteamine	0-3	BCL2 apoptosis regulator	Homo sapiens	32-36	
20118770-16	2010	Familiarity with the morphologic and immunophenotypic spectrum of DHL is important in directing testing to detect concurrent IGH-BCL2 and MYC rearrangements when a karyotype is unavailable.	Cysteamine	66-69	BCL2 apoptosis regulator	Homo sapiens	129-133	
26834954-2	2016	The most commonly seen DHL is diffuse large B-cell lymphoma (DLBCL) with t(14;18) and t(8;14) or t(8;22) resulting in overexpression of BCL2 and MYC, respectively.	Cysteamine	23-26	BCL2 apoptosis regulator	Homo sapiens	136-140	
28061782-5	2017	RESULTS: Three cases of DHL were detected: two with translocations of MYC and BCL2 and one with translocations of MYC and BCL6, all leading to death in less than six months.	Cysteamine	24-27	BCL2 apoptosis regulator	Homo sapiens	78-82	
28766546-3	2017	The majority of DHL is represented by s-MYC/BCL2 cases.	Cysteamine	16-19	BCL2 apoptosis regulator	Homo sapiens	44-48	
31752970-11	2019	Notably, in a mouse model of DHL bearing primary tumor cells derived from lymphoma patients, combined treatment with XPO1 and BCL2 inhibitors blocks tumor progression, prevents brain metastasis, and extends host survival.	Cysteamine	29-32	BCL2 apoptosis regulator	Homo sapiens	126-130	
31117849-10	2019	Targeted approaches, especially chimeric antigen receptor T-cell therapies and small-molecule inhibitors targeting myc or bcl-2, exhibit the potential of improving outcomes for patients with DHL.	Cysteamine	191-194	BCL2 apoptosis regulator	Homo sapiens	122-127	
29931583-9	2019	These results provide a rationale for dual targeting of BRD4 and BCL2 using AZD5153 and AZD4320 as a therapeutic strategy against DHL and DEL.	Cysteamine	130-133	BCL2 apoptosis regulator	Homo sapiens	65-69	
29353886-9	2018	Together, these findings highlight the relevance of BFL-1 in DH lymphoma-associated drug resistance and support the combined use of a BCL-2 antagonist and a BET inhibitor as a promising therapeutic strategy for patients with aggressive DHL.	Cysteamine	236-239	BCL2 apoptosis regulator	Homo sapiens	134-139	
28711572-2	2017	DHL encompasses various histologies of lymphomas where the MYC oncogene and either BCL2 or BCL6 oncogenes are present concomitantly.	Cysteamine	0-3	BCL2 apoptosis regulator	Homo sapiens	83-87	
26717387-8	2015	Cooccurrence of TP53 and BCL2 aberrations ameliorated the poor prognostic impact of single TP53+ or BCL2+ in MYC positive patients.This pilot study generates evidence for the complex interplay between the alterations of genetic pathways in DLBCL, which goes beyond the concept of DHL.	Cysteamine	280-283	BCL2 apoptosis regulator	Homo sapiens	25-29	
26717387-8	2015	Cooccurrence of TP53 and BCL2 aberrations ameliorated the poor prognostic impact of single TP53+ or BCL2+ in MYC positive patients.This pilot study generates evidence for the complex interplay between the alterations of genetic pathways in DLBCL, which goes beyond the concept of DHL.	Cysteamine	280-283	BCL2 apoptosis regulator	Homo sapiens	100-104	
24679006-6	2015	Our findings indicate a significant difference between these two types of DHL at a molecular level with pathogenetic implications, as arguably, TP53 mutations inhibiting p53 mediated promotion of apoptosis pose a synergistic advantage in clonal evolution of cells with malignantly enforced overexpression of BCL2.	Cysteamine	74-77	BCL2 apoptosis regulator	Homo sapiens	308-312	
26824820-7	2015	The DHL group showed a correlation between the rearrangement of the BCL2+/MYC+ genes and the expression of MYC and BCL2 proteins in 5 out of 6 patients.	Cysteamine	4-7	BCL2 apoptosis regulator	Homo sapiens	68-72	
26824820-7	2015	The DHL group showed a correlation between the rearrangement of the BCL2+/MYC+ genes and the expression of MYC and BCL2 proteins in 5 out of 6 patients.	Cysteamine	4-7	BCL2 apoptosis regulator	Homo sapiens	115-119